AWM
SUPN icon

AE Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

AE Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,923
Closed -$429K – 1889
2023
Q4 		$429K Buy
+14,923
New +$396K ﹤0.01% 1533

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

AE Wealth Management's SUPN Position: Q1 2024 in Review

AE Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2024, closing a stake of 14,923 shares — an estimated $429K sold.

AE Wealth Management first reported a position in SUPN in Q4 2023 and held it in 1 quarter. The position peaked at $429K in Q4 2023. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

  • AE Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 14,923 Supernus Pharmaceuticals shares in Q1 2024, an estimated $429K.
  • AE Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • AE Wealth Management's Supernus Pharmaceuticals position peaked at $429K in Q4 2023.
  • 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.